200 related articles for article (PubMed ID: 32572160)
1. Functional genomics identifies new synergistic therapies for retinoblastoma.
Aubry A; Pearson JD; Huang K; Livne-Bar I; Ahmad M; Jagadeesan M; Khetan V; Ketela T; Brown KR; Yu T; Lu S; Wrana JL; Moffat J; Bremner R
Oncogene; 2020 Jul; 39(31):5338-5357. PubMed ID: 32572160
[TBL] [Abstract][Full Text] [Related]
2. Co-deleting Pten with Rb in retinal progenitor cells in mice results in fully penetrant bilateral retinoblastomas.
Xie C; Lu H; Nomura A; Hanse EA; Forster CL; Parker JB; Linden MA; Karasch C; Hallstrom TC
Mol Cancer; 2015 Apr; 14():93. PubMed ID: 25907958
[TBL] [Abstract][Full Text] [Related]
3. Differential gene expression profile of retinoblastoma compared to normal retina.
Ganguly A; Shields CL
Mol Vis; 2010 Jul; 16():1292-303. PubMed ID: 20664703
[TBL] [Abstract][Full Text] [Related]
4. Thrombospondin-1 might be a therapeutic target to suppress RB cells by regulating the DNA double-strand breaks repair.
Chen P; Yu N; Zhang Z; Zhang P; Yang Y; Wu N; Xu L; Zhang J; Ge J; Yu K; Zhuang J
Oncotarget; 2016 Feb; 7(5):6105-20. PubMed ID: 26756218
[TBL] [Abstract][Full Text] [Related]
5. Differential microRNA-34a expression and tumor suppressor function in retinoblastoma cells.
Dalgard CL; Gonzalez M; deNiro JE; O'Brien JM
Invest Ophthalmol Vis Sci; 2009 Oct; 50(10):4542-51. PubMed ID: 19443717
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylation of pRb: mechanism for RB pathway inactivation in MYCN-amplified retinoblastoma.
Ewens KG; Bhatti TR; Moran KA; Richards-Yutz J; Shields CL; Eagle RC; Ganguly A
Cancer Med; 2017 Mar; 6(3):619-630. PubMed ID: 28211617
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of the p53 pathway in retinoblastoma.
Laurie NA; Donovan SL; Shih CS; Zhang J; Mills N; Fuller C; Teunisse A; Lam S; Ramos Y; Mohan A; Johnson D; Wilson M; Rodriguez-Galindo C; Quarto M; Francoz S; Mendrysa SM; Guy RK; Marine JC; Jochemsen AG; Dyer MA
Nature; 2006 Nov; 444(7115):61-6. PubMed ID: 17080083
[TBL] [Abstract][Full Text] [Related]
8. Next-Generation Technologies and Strategies for the Management of Retinoblastoma.
Gudiseva HV; Berry JL; Polski A; Tummina SJ; O'Brien JM
Genes (Basel); 2019 Dec; 10(12):. PubMed ID: 31835688
[TBL] [Abstract][Full Text] [Related]
9. Developmental stage-specific proliferation and retinoblastoma genesis in RB-deficient human but not mouse cone precursors.
Singh HP; Wang S; Stachelek K; Lee S; Reid MW; Thornton ME; Craft CM; Grubbs BH; Cobrinik D
Proc Natl Acad Sci U S A; 2018 Oct; 115(40):E9391-E9400. PubMed ID: 30213853
[TBL] [Abstract][Full Text] [Related]
10. The RB protein family in retinal development and retinoblastoma: new insights from new mouse models.
Bremner R; Chen D; Pacal M; Livne-Bar I; Agochiya M
Dev Neurosci; 2004; 26(5-6):417-34. PubMed ID: 15855771
[TBL] [Abstract][Full Text] [Related]
11. The genetics of retinoblastoma. Relevance to the patient.
Gallie BL; Dunn JM; Chan HS; Hamel PA; Phillips RA
Pediatr Clin North Am; 1991 Apr; 38(2):299-315. PubMed ID: 2006079
[TBL] [Abstract][Full Text] [Related]
12. The Oncogene
Sradhanjali S; Rout P; Tripathy D; Kaliki S; Rath S; Modak R; Mittal R; Chowdary TK; Reddy MM
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680394
[TBL] [Abstract][Full Text] [Related]
13. The radioprotector ortho-phospho-L-tyrosine (pTyr) attenuates the side effects of fractionated irradiation in retinoblastoma mouse models but also decreases the local tumour control.
Tschulakow AV; Dittmann K; Huber SM; Klumpp D; Stegen B; Schraermeyer U; Rodemann HP; Julien-Schraermeyer S
Radiother Oncol; 2017 Sep; 124(3):462-467. PubMed ID: 28711224
[TBL] [Abstract][Full Text] [Related]
14. Subconjunctival topotecan in fibrin sealant in the treatment of transgenic murine retinoblastoma.
Tsui JY; Dalgard C; Van Quill KR; Lee L; Grossniklaus HE; Edelhauser HF; O'Brien JM
Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):490-6. PubMed ID: 18234990
[TBL] [Abstract][Full Text] [Related]
15. Spectrum of germline
Rojanaporn D; Boontawon T; Chareonsirisuthigul T; Thanapanpanich O; Attaseth T; Saengwimol D; Anurathapan U; Sujirakul T; Kaewkhaw R; Hongeng S
Mol Vis; 2018; 24():778-788. PubMed ID: 30636860
[TBL] [Abstract][Full Text] [Related]
16. Induction of a retinoblastoma phosphatase activity by anticancer drugs accompanies p53-independent G1 arrest and apoptosis.
Dou QP; An B; Will PL
Proc Natl Acad Sci U S A; 1995 Sep; 92(20):9019-23. PubMed ID: 7568064
[TBL] [Abstract][Full Text] [Related]
17. UHRF1 downmodulation enhances antitumor effects of histone deacetylase inhibitors in retinoblastoma by augmenting oxidative stress-mediated apoptosis.
Kim JK; Kan G; Mao Y; Wu Z; Tan X; He H; Lee C
Mol Oncol; 2020 Feb; 14(2):329-346. PubMed ID: 31782885
[TBL] [Abstract][Full Text] [Related]
18. Rb is required for retinal angiogenesis and lamination.
Zhou Y; Wei R; Zhang L; Chen Y; Lu S; Liang C; Wang Y; Xiao L; Zhang J; Bremner R; Chen D
Cell Death Dis; 2018 Mar; 9(3):370. PubMed ID: 29511172
[TBL] [Abstract][Full Text] [Related]
19. miRNA signature identification of retinoblastoma and the correlations between differentially expressed miRNAs during retinoblastoma progression.
Yang Y; Mei Q
Mol Vis; 2015; 21():1307-17. PubMed ID: 26730174
[TBL] [Abstract][Full Text] [Related]
20. MDM2 but not MDM4 promotes retinoblastoma cell proliferation through p53-independent regulation of MYCN translation.
Qi DL; Cobrinik D
Oncogene; 2017 Mar; 36(13):1760-1769. PubMed ID: 27748758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
